This new agent represents a new approach to the treatment of erosive inflammatory arthritis. On the surface, using a drug with no effect on articular inflammation may not sound viable. However, it is compelling to contemplate combination regimens with denosumab that may result in control of articular signs and symptoms with concomitant suppression of erosions with little risk of additional toxic side effects. It is interesting to note that joint space narrowing was not suppressed by denosumab, suggesting that the mechanisms of cartilage destruction and erosions are distinct in RA. The efficacy of denosumab to treat post-menopausal osteoporosis is a potential added benefit.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.